Dhurandhar box office: Ranveer Singh makes a strong comeback, film opens at Rs 27 crore_我的网站
一 | Ranveer Singh's Dhurandhar had an explosive opening at the Indian box office. The Aditya Dhar directorial is a spy thriller revolving around a RAW agent and his covert missions in the criminal underworld of Karachi and its link to India. According to industry tracker Sacnilk, the film has earned Rs 27 crore on its release day, December 5.
This surpasses the predictions made by trade experts, who estimated the film's opening day earnings to fall in the range of Rs 15-18 crore. With a stronger start than Saiyaara, which collected Rs ₹21.50 crore on Day 1, Dhurandhar has already outperformed expectations.
It has also come very close to Chhaava's opening day collection of Rs 31 crore, making it a solid comeback for Singh. Dhurandhar has now recorded the third-biggest opening of 2025 after War 2 (Rs 52 crore) and Chhaava. It also stands as Ranveer Singh's biggest opener to date, surpassing his previous record, Simmba, which opened at Rs 20 crore in 2018.
Besides Ranveer, Dhurandhar features an ensemble cast featuring Akshaye Khanna, R Madhavan, Sanjay Dutt, Sara Arjun, Rakesh Bedi and Arjun Rampal among others.
Filmfare's Review of Dhurandhar
Filmfare rated the film 3.5 out of 5 and said in its review, "At the centre of this world stands Ranveer Singh, playing the hard-edged agent who slips into the shadow world of sleeper operatives as a cross-border conspiracy erupts. It’s a performance of restraint, a departure from his flamboyant screen persona. This Ranveer is raw yet internalised, driven yet fraying. The role demands both physical ferocity and emotional weariness, and he delivers both with remarkable control. His silences speak as loudly as his action beats, grounding the film even when its narrative ambitions begin to overtake its focus."
Meanwhile, Dhurandhar's sequel will be released in March next year.
Also Read: Yami Gautam Praises Aditya Dhar’s Hard Work As Dhurandhar Releases in Theatres。
二 |
The Biden administration is eyeing mid-September for the rollout of updated COVID-19 vaccines, according to Food and Drug Administration and Centers for Disease Control and Prevention officials.
“Vaccination is going to continue to be key this year because immunity wanes and because the COVID-19 virus continues to change,” an official said on a call with reporters. “For those reasons, vaccines remain the best protection against hospitalization and death.”
It’s the first time that vaccines for all three of the major fall and winter viruses – flu, COVID-19 and respiratory syncytial virus – will be available.
The announcement comes as COVID-19 hospitalizations are increasing and the Biden administration hopes to get ahead of any potential fall or winter coronavirus wave with its vaccine campaign.
Moderna, Pfizer and Novavax have developed updated coronavirus vaccines that will target the XBB.1.5 strain, which was responsible for less than 5% of new infections in recent weeks, according to CDC data.
The dominant strain circulating now is EG.5 – nicknamed “eris” – that is causing over 20% of new cases.
Eris appears more transmissible and better able to evade immunity provided by vaccines and previous infection, according to the World Health Organization, but it hasn’t been associated with more severe disease.
Another variant to watch is BA.2.86, which quickly caught the attention of both WHO and the CDC. The highly mutated strain is likely not responsible for the recent rise in hospitalizations in the U.S., according to the CDC, but it is too soon to know the new strain’s transmissibility or severity.
Officials believe the updated shots will work against these strains.
“FDA expects that once available, the updated vaccines will similarly provide protection against the most serious outcomes of the disease that may result from currently circulating variants,” one of the officials said.
The CDC’s committee of outside vaccine experts will meet in mid-September to recommend who should get the updated COVID-19 vaccines. The officials noted that for some people, including older or immunocompromised Americans, more than one shot per year may be needed.
。
三 |
Current article:http://fku9.gangzhengganfouanlou.pics/news/20260826_263373.html
